Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Healthcare Sector Analysis

UpdatedAug 15, 2026
DataAggregated Company Financials
Companies84
  • 7D-4.3%
  • 3M-9.7%
  • 1Y3.1%
  • YTD-10.6%

Over the last 7 days, the Healthcare industry has dropped 2.0%, driven by declines in AstraZeneca and GSK of 3.7% and 7.3%, respectively. On the other hand NIOX Group is actually up 8.7%. In the past year, the industry has gained 5.2%. Looking forward, earnings are forecast to grow by 13% annually.

Sector Valuation and Performance

Has the U.K. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 15 Aug 2026UK£310.4bUK£104.0bUK£14.7b28.7x21.2x3x
Mon, 13 Jul 2026UK£337.4bUK£103.2bUK£16.1b25.7x20.9x3.3x
Wed, 10 Jun 2026UK£345.4bUK£103.3bUK£16.1b27.6x21.4x3.3x
Fri, 08 May 2026UK£343.2bUK£102.4bUK£16.0b25.9x21.4x3.4x
Sun, 05 Apr 2026UK£385.0bUK£102.6bUK£16.2b20.6x23.8x3.8x
Tue, 03 Mar 2026UK£396.6bUK£101.2bUK£16.0b23.5x24.8x3.9x
Thu, 29 Jan 2026UK£346.4bUK£98.9bUK£14.8b25.2x23.4x3.5x
Sat, 27 Dec 2025UK£347.0bUK£100.1bUK£15.0b21.9x23.2x3.5x
Mon, 24 Nov 2025UK£350.0bUK£101.6bUK£15.2b23.8x23.1x3.4x
Wed, 22 Oct 2025UK£324.0bUK£98.7bUK£12.1b25.9x26.8x3.3x
Fri, 19 Sep 2025UK£299.7bUK£100.6bUK£12.0b28.8x24.9x3x
Sun, 17 Aug 2025UK£304.5bUK£100.5bUK£12.0b29.3x25.4x3x
Tue, 15 Jul 2025UK£286.8bUK£97.1bUK£10.8b30.2x26.5x3x
Thu, 12 Jun 2025UK£298.3bUK£96.9bUK£10.7b29.5x27.8x3.1x
Sat, 10 May 2025UK£281.4bUK£97.9bUK£10.8b30.2x25.9x2.9x
Mon, 07 Apr 2025UK£288.1bUK£98.7bUK£9.7b28.7x29.7x2.9x
Wed, 05 Mar 2025UK£317.6bUK£99.2bUK£9.7b29.6x32.8x3.2x
Fri, 31 Jan 2025UK£262.4bUK£86.4bUK£7.7b30.2x34.1x3x
Sun, 29 Dec 2024UK£246.0bUK£85.9bUK£7.6b31.3x32.2x2.9x
Tue, 26 Nov 2024UK£247.4bUK£86.0bUK£7.7b27.7x32.3x2.9x
Thu, 24 Oct 2024UK£274.1bUK£83.1bUK£8.9b25.6x30.6x3.3x
Sat, 21 Sep 2024UK£276.9bUK£81.6bUK£8.8b29.3x31.5x3.4x
Mon, 19 Aug 2024UK£299.6bUK£82.8bUK£9.0b33.9x33.5x3.6x
Wed, 17 Jul 2024UK£279.7bUK£80.8bUK£9.3b31.8x30.1x3.5x
Fri, 14 Jun 2024UK£289.5bUK£81.5bUK£9.4b31.2x30.8x3.6x
Sun, 12 May 2024UK£296.7bUK£82.4bUK£9.5b34.4x31.4x3.6x
Tue, 09 Apr 2024UK£263.2bUK£81.0bUK£9.6b32.6x27.4x3.3x
Thu, 07 Mar 2024UK£258.6bUK£80.5bUK£9.5b35.1x27.1x3.2x
Sat, 03 Feb 2024UK£272.1bUK£84.9bUK£9.5b38.7x28.6x3.2x
Mon, 01 Jan 2024UK£270.1bUK£83.8bUK£10.6b40.4x25.4x3.2x
Wed, 29 Nov 2023UK£255.9bUK£84.0bUK£10.7b39.6x24x3x
Fri, 27 Oct 2023UK£266.7bUK£86.3bUK£10.3b39.9x25.8x3.1x
Sun, 24 Sep 2023UK£282.1bUK£85.8bUK£10.3b40.3x27.3x3.3x
Tue, 22 Aug 2023UK£268.9bUK£83.9bUK£10.1b39.7x26.5x3.2x
Price to Earnings Ratio

26.5x


Total Market Cap: UK£268.9bTotal Earnings: UK£10.1bTotal Revenue: UK£83.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Healthcare Sector Price to Earnings3Y Average 27.2x202420252026
Current Industry PE
  • Investors are pessimistic on the British Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 21.5x which is lower than its 3-year average PE of 27.2x.
  • The industry is trading close to its 3-year average PS ratio of 3.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 13% per year over the last three years.
  • Revenues for these companies have grown 7.5% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare sector?

GB Market-1.35%
Healthcare-4.33%
Healthcare Services0.42%
Medical Equipment-1.09%
Biotech-1.95%
Healthtech-2.47%
Life Sciences-2.70%
Pharma-4.57%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio.
    • Analysts are expecting annual earnings growth of 9.9%, which is lower than the prior year's growth of 51.1% per year.
Forecasted Growth
  • Analysts are most optimistic on the Life Sciences industry, expecting annual earnings growth of 51% over the next 5 years.
  • In contrast, the Biotech industry is expected to see its earnings grow by 9.6% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NIOX NIOX GroupUK£0.688.7%
+UK£22.7m		0.9%PE40.6x
HCM HUTCHMED (China)UK£1.850.5%
+UK£8.7m		-23.9%PE121.7x
IDHC Integrated Diagnostics HoldingsUS$0.542.9%
+US$8.7m		28.9%PE10.8x
STX Shield TherapeuticsUK£0.04314.5%
+UK£5.9m		-23.0%PS1.3x
SAR Sareum HoldingsUK£0.2715.2%
+UK£4.8m		35.9%PB30.8x

Latest News

AZN
UK£114.60
AstraZeneca
7D
-3.7%
1Y
-1.1%
HCM
UK£1.85
HUTCHMED (China)
7D
0.5%
1Y
-23.9%
GSK
UK£18.18
GSK
7D
-7.3%
1Y
27.5%
HIK
UK£16.40
Hikma Pharmaceuticals
7D
-2.2%
1Y
-8.5%
GNS
UK£22.56
Genus
7D
-2.1%
1Y
-13.2%
HLN
UK£3.56
Haleon
7D
-3.7%
1Y
-0.2%
CTEC
UK£2.30
Convatec Group
7D
-1.2%
1Y
0.7%
SN.
UK£10.96
Smith & Nephew
7D
-1.5%
1Y
-18.5%
Narrative Update • Aug 05

SN.: Share Buybacks And New Surgical Technologies Will Drive Future Upside

Analysts have trimmed their price target on Smith & Nephew to £13.26 from £13.69, reflecting updated views on a slightly lower fair value, a modestly adjusted discount rate, and expectations for a different balance between revenue growth, profit margins and future P/E multiples. What’s in the News for Smith & Nephew Issued earnings guidance for the second half of 2026, with expected revenue growth in a range of 5.0% to 5.5%.
STX
UK£0.043
Shield Therapeutics
7D
14.5%
1Y
-23.0%
TSTL
UK£4.20
Tristel
7D
2.4%
1Y
16.7%
SAR
UK£0.27
Sareum Holdings
7D
15.2%
1Y
35.9%
ONT
UK£1.22
Oxford Nanopore Technologies
7D
-2.3%
1Y
-42.0%
Analysis Article • Jul 14

Oxford Nanopore Technologies (LON:ONT) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
IDHC
US$0.54
Integrated Diagnostics Holdings
7D
2.9%
1Y
28.9%
CVSG
UK£13.07
CVS Group
7D
0.5%
1Y
5.7%
Narrative Update • Jun 24

CVSG: Share Buyback Momentum Will Support Future Upside Potential

Analysts have kept their fair value estimate for CVS Group steady at £16.40, with small adjustments to assumptions such as the discount rate and future P/E leading to only a marginal change in the overall price target narrative. What’s in the News for CVS Group CVS Group commenced a share repurchase program on May 26, 2026, committing up to £50 million to buy back its shares.
4BB
UK£5.50
4basebio
7D
4.8%
1Y
-38.9%
NIOX
UK£0.68
NIOX Group
7D
8.7%
1Y
0.9%